Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2025-03-14 AGM Information
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for GemVax. It outlines the date, location, and agenda items (approval of financial statements, election of directors and auditors, and remuneration limits). This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of upcoming meeting details and agenda items, which falls under the PSI category.
2025-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for GemVax & KAEL. It includes the meeting date, location, agenda items (financial statement approval, director appointments, etc.), and voting procedures. This document is a standard proxy statement/notice of meeting sent to shareholders to inform them of the upcoming AGM and solicit their votes, which fits the 'Proxy Solicitation & Information Statement' category.
2025-03-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used to disclose changes in share ownership by insiders or major shareholders. According to the provided definitions, reports of personal share transactions by company directors and executives (insider trades) fall under the 'Director's Dealing' (DIRS) category.
2025-02-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including acquisitions, disposals, and collateral agreements by major shareholders and special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-02-28 Korean
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from a South Korean company, GemVax & Kael, detailing the issuance of bonds with warrants (신주인수권부사채 발행결정). It includes specific financial terms, maturity dates, conversion/exercise prices, and the purpose of the funds. This type of filing is a regulatory requirement for capital structure changes and financing activities, which falls under the 'Capital/Financing Update' category.
2025-02-21 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the 'Results of Securities Issuance' (증권 발행결과) for GemVax. It details the issuance of private placement bonds with warrants (BW), including the total amount issued (10 billion KRW) and the payment date. This falls under the category of capital structure changes and financing activities, specifically matching the 'Capital/Financing Update' (CAP) classification.
2025-02-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.